Ly93 is a selective and orally active sphingomyelin synthase 2 (SMS2) inhibitor, with an IC50 of 91 nM[1].
Ly93 is a selective and orally active sphingomyelin synthase 2 (SMS2) inhibitor, with an IC50 of 91 nM[1].
Ly93 (100 mg/kg, i.g. once daily for 7 days) significantly decreases the plasma SM levels of C57BL/6J mice[1].Ly93 dose-dependently attenuates the atherosclerotic lesions in the root and the entire aorta as well as macrophage content in lesions, in apolipoprotein E gene knockout mice[1].
Ly93 (100 mg/kg, i.g. once daily for 7 days) significantly decreases the plasma SM levels of C57BL/6J mice[1].
Ly93 dose-dependently attenuates the atherosclerotic lesions in the root and the entire aorta as well as macrophage content in lesions, in apolipoprotein E gene knockout mice[1].
| Animal Model: | C57BL/6J mice[1]. |
| Dosage: | 100 mg/kg. |
| Administration: | I.G. (gavage) once daily for 7 days. |
| Result: | Significantly decreased the plasma SM levels compared with vehicle group. |
| Animal Model: | ApoE KO mice (eight-week-old)[1]. |
| Dosage: | 12.5 or 40 mg/kg. |
| Administration: | I.G. (gavage) once daily. |
| Result: | The levels of ALT and AST in the plasma of apoE KO mice did not show statistic changes when compared with the control group. |
[1]. Li Y, et al. Discovery, synthesis and anti-atherosclerotic activities of a novel selective sphingomyelin synthase 2 inhibitor. Eur J Med Chem. 2019 Feb 1;163:864-882.
